fda and glp-1 The FDA-approved pill for weight loss works differently than you might think. Swipe to see how → 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘪𝘯 𝘢𝘭𝘭 50 𝘴𝘵𝘢𝘵𝘦𝘴. 𝘗𝘳𝘦𝘴𝘤𝘳𝘪𝘱𝘵𝘪𝘰𝘯 𝘳𝘦𝘲𝘶𝘪𝘳𝘦𝘥. 𝘞𝘦𝘪𝘨𝘩𝘵 𝘓𝘰𝘴𝘴 𝘣𝘺 𝘏𝘪𝘮𝘴 𝘪𝘴 𝘢 Exploration of the potential association

Lancet 2022;400:186981.ArticlePubMed 114

The NICE criteria are as follows: NICE recommends GLP-1 analogues or Tirzepatide (Mounjaro) for the treatment of adults with type 2 diabetes alongside diet and exercise when diabetes is insufficiently controlled, only if: triple therapy with metformin and 2 other oral antidiabetic drugs is ineffective, not tolerated or contraindicated, and a person has a body mass index (BMI) of 35 kg/m2 or more, and specific psychological or other medical problems associated with obesity, or a person has a BMI of less than 35 kg/m2, and: Insulin therapy would have significant occupational implications, or Weight loss would benefit other significant obesity-related complications

Starting with the lowest dose and extending the intervals between dose increases may improve tolerance, as determined by the prescribing clinician

Unlike quick-fix weight loss trends, GLP-1 therapy aligns with the body's natural processes, which supports long-term weight loss success

In May, Otsuka and Lundbeck received FDA approval for Rexulti (brexpiprazole) for the treatment of agitation symptoms associated with dementia due to Alzheimers disease